
    trial stopped for futility
  
['pulmonary arterial hypertension']
['inhaled nitric oxide 75 mcg/kg ibw/hr', 'placebo']

        Inclusion Criteria:

          1. Signed Informed Consent Form (and assent as appropriate) prior to the initiation of
             any study mandated procedures or assessments

          2. A confirmed diagnosis of PAH Group 1 who have either idiopathic PAH (IPAH), heritable
             PAH, drug and toxin-induced PAH, associated PAH (APAH) with connective tissue disease
             (CTD), APAH with repaired simple congenital systemic to pulmonary shunt (i.e., atrial
             septal defect, ventricular septal defect and/or patent ductus arteriosus; complete
             repair at least 1 year prior to Screening), APAH with human immunodeficiency virus
             (HIV), or APAH with portal hypertension

          3. Subjects receiving at least one PAH specific therapy (ERA or PDE-5 inhibitor, or
             inhaled, subcutaneous, or intravenous prostacyclin or a prostacyclin analog) with the
             same type of therapy for at least 3 months with stable dosing 4 weeks prior to
             Screening. (Subjects should be receiving optimal therapy according to the disease
             severity)

          4. Subjects using oxygen therapy by nasal cannula for at least 4 weeks prior to Screening

          5. PAH diagnosis confirmed by RHC within the previous 5 years, according to the following
             definitions:

               -  PVR ≥ 400 dynes.sec.cm-5 (5 Wood units)

               -  mPAP ≥ 25 mmHg

               -  PCWP or LVEDP ≤ 15 mmHg

               -  Subjects who otherwise meet all the inclusion criteria and none of the exclusion
                  criteria but have not undergone a RHC within the previous 5 years may be
                  considered eligible for the study if they undergo a RHC and then meet the
                  pulmonary hemodynamics criterion

          6. 6MWD ≥ 100 meters and ≤ 450 meters prior to randomization

          7. WHO Functional Class II-IV. Subjects with WHO Functional Class IV should be treated
             with prostacyclin or a prostacyclin analog (subcutaneous or intravenous), plus at
             least one additional PAH specific therapy (ERA or PDE-5), if available to the subject
             and reimbursed by health insurance

          8. Age between 18 and 85 years (inclusive)

          9. Willingness to use INOpulse delivery device for at least 12 hours per day

         10. Willingness to continue on study drug until the subject has completed Week 18
             assessments

         11. Female subjects of childbearing potential must have a negative pre-treatment pregnancy
             test (serum or urine). All female subjects should take adequate precaution to avoid
             pregnancy.

        Exclusion Criteria:

        1. Subjects with known HIV infection who have a history within the past 3 months of any
        opportunistic pulmonary disease (e.g., tuberculosis, Pneumocystis carinii pneumonia, or
        other pneumonias) at the time of Screening 2. PAH associated with untreated thyroid
        disorders, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic
        telangiectasia, hemoglobinopathies, myeloproliferative disorders or splenectomy 3. Subjects
        with pulmonary conditions that may contribute to PAH including, but not limited to, chronic
        bronchiectasis, cystic fibrosis, or other pulmonary condition that the Investigator may
        deem to contribute to the severity of the disease or impair the delivery of iNO due to
        airway disease 4. Subjects receiving riociguat 5. Subjects receiving oral prostanoids as
        monotherapy 7. PAH associated with significant venous or capillary involvement, known or
        suspected pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis 8. Any
        subject with WHO PH Groups 2, 3, 4 or 5 9. Subjects with any of the following cardiac
        abnormalities:

        a. Underlying cardiomyopathy or clinically significant aortic or mitral valve disease in
        the opinion of the investigator b. Left ventricular systolic dysfunction (LVSD), i.e., left
        ventricular ejection fraction (LVEF) < 40% or left ventricular shortening fraction (LVSF) <
        22%, as determined by local reading c. Current symptomatic coronary artery disease,
        myocardial infarction within 1 year, or any coronary artery interventions within 6 months
        10. Systemic hypertension defined as systolic blood pressure (SBP) > 160 mmHg and/or
        diastolic blood pressure (DBP) > 100 mmHg persistent at Screening after a period of rest
        (treated or untreated) 11. Subjects with a history of deep vein thrombosis, pulmonary
        embolism/infarction or prothrombotic disorder must have had chronic thromboembolic
        pulmonary hypertension (CTEPH) excluded by ventilation/perfusion lung (V/Q) scan 12. Severe
        obstructive lung disease defined as both a forced expiratory volume in 1 second/forced
        vital capacity (FEV1/FVC) < 70% and FEV1 < 55% of predicted value 13. Moderate to severe
        restrictive lung disease: total lung capacity (TLC) < 60% of predicted; if TLC 60% to 70%
        predicted, a high resolution CT scan showing diffuse disease or more than mild patchy
        disease 14. Any subject who develops or has developed a PCWP > 20 mmHg during acute
        vasodilator testing (AVT) 15. Systemic hypotension defined as SBP < 90 mmHg persistent at
        Screening after a period of rest 16. Moderate to severe hepatic impairment, i.e.,
        Child-Pugh Class B or C 17. On dialysis 18. Acute or chronic physical impairment (other
        than dyspnea due to PAH) that would limit the ability to comply with study procedures or
        adherence to therapy (i.e., 6MWT), including carrying and wearing the pulsed delivery
        device per study protocol, or medical problem(s) likely to preclude completion of the study
        19. Pregnant or breastfeeding females at Screening 20. Administered L-arginine within 1
        month prior to Screening 21. Known concomitant life-threatening disease with a life
        expectancy less than 1 year 22. Atrial septostomy within 3 months preceding randomization
        23. The concurrent use of the INOpulse device with a continuous positive airway pressure
        (CPAP), Bilevel positive airway presure BiPAP, or any other positive pressure device.

        24. Use of investigational drugs or devices within 1 month prior to Screening (other than
        acute vasodilator testing with iNO) 25. Any underlying medical or psychiatric condition
        that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the
        study 26. Any subject who has been enrolled in any previous clinical study with inhaled NO
        administered through pulse delivery.
      